An improved vasoactive drug combination for a pharmacological erection program.

Area of Science:

• Pharmacology
• Urology
• Andrology

Background:

• Erectile dysfunction (ED) affects a significant number of men, necessitating effective therapeutic options.
• Current treatments for ED have limitations, driving the need for novel pharmacological approaches.
• Vasoactive agents are crucial in managing ED, particularly for improving blood flow and smooth muscle relaxation.

Purpose of the Study:

• To develop and evaluate a potent vasoactive drug combination for pharmacological erection programs.
• To assess the efficacy and safety of this novel combination in patients with diverse types of erectile dysfunction.
• To establish optimal dosing and storage guidelines for the prepared vasoactive solution.

Main Methods:

• A combination therapy was formulated using papaverine hydrochloride, phentolamine mesylate, and prostaglandin E1 in specific ratios.
• The stability and storage conditions of the prepared vasoactive solution were determined.
• The efficacy and safety of the drug combination were assessed in 116 patients undergoing diagnostic testing and treatment for ED.

Main Results:

• The vasoactive drug combination demonstrated physiological activity for at least 6 months at room temperature.
• A dose of 0.25 cc was effective for diagnosis and treatment in most patients with mild to moderate ED.
• Patients with neurogenic dysfunction typically required a lower dose (0.1-0.125 cc).
• Adverse events were minimal, with only two cases of prolonged erection requiring irrigation and two patients reporting pain.

Conclusions:

• The developed vasoactive drug combination is a potent and effective therapeutic option for erectile dysfunction.
• The therapy is well-tolerated, with a low incidence of significant side effects such as pain or fibrosis.
• This pharmacological approach offers a viable treatment for a broad spectrum of patients with erectile dysfunction.